Seroatlas · Human Serome Atlas

LYPD1

Ly6/PLAUR domain-containing protein 1

Also known as: LYPD1_HUMAN, LYPDC1, MGC29643

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8N2G4
Gene: LYPD1
Ensembl: ENSG00000150551
Chromosome: 2
Canonical length: 141 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Vesicles,Plasma membrane
Secretome location: Intracellular and membrane

OverviewNCBI Gene

Predicted to enable acetylcholine receptor inhibitor activity. Predicted to be involved in acetylcholine receptor signaling pathway. Predicted to act upstream of or within several processes, including behavioral fear response; cholinergic synaptic transmission; and negative regulation of protein localization to plasma membrane. Predicted to be located in extracellular region and plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

141 residues, UniProt reviewed canonical sequence.

>Q8N2G4|LYPD1
     1  MWVLGIAATF CGLFLLPGFA LQIQCYQCEE FQLNNDCSSP EFIVNCTVNV QDMCQKEVME
    61  QSAGIMYRKS CASSAACLIA SAGYQSFCSP GKLNSVCISC CNTPLCNGPR PKKRGSSASA
   121  LRPGLRTTIL FLKLALFSAH C

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LYPD1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.44
Highest tissue expression: 50 nTPM

Expression across tissuesHPA

Tissue

fallopian tube: 50 nTPM
basal ganglia: 36 nTPM
midbrain: 25 nTPM
hypothalamus: 23 nTPM
hippocampal formation: 22 nTPM
amygdala: 20 nTPM

Single-cell type

fallopian secretory cells: 249 nCPM
oocytes: 175 nCPM
pituitary stem cells: 129 nCPM
oligodendrocyte progenitor cells: 57 nCPM
ependymal cells: 52 nCPM
epididymal efferent duct ciliated cells: 47 nCPM

Immune cell

eosinophil: 3.6 nTPM
basophil: 0.6 nTPM
naive B-cell: 0.1 nTPM
classical monocyte: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

hypothalamus: 39 nTPM
medulla oblongata: 38 nTPM
midbrain: 37 nTPM
thalamus: 34 nTPM
pons: 32 nTPM
spinal cord: 31 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.74
gnomAD pLI: 0
gnomAD missense Z: 0.5
DepMap mean gene effect: -0.04
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of LYPD1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

CHRNA4

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LYPD1 as an antibody target. Whether an autoantibody or antibody against LYPD1 could matter depends on whether native LYPD1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LYPD1 is annotated at the cell surface, where native LYPD1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LYPD1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...